Skip to main content

Table 3 Comparison of pregnancy outcomes

From: Analysis of euploidy rates in preimplantation genetic testing for aneuploidy cycles with progestin-primed versus GnRH agonist/antagonist protocol

Variables

Ovarian stimulation protocol

p value

PPOS

GnRH agonist

GnRH antagonist

Patients (n)

58

88

130

 

Endometrial preparation, (%)*

Natural cycles

8.62%(5/58)

38.64%(34/88)

20%(26/130)

0000a,c

Clomid-induced

17.24%(10/58)

9.09%(8/88)

7.69%(10/130)

0.124

Hormonal cycles

75.86%(44/58)

52.27%(46/88)

72.31%(94/130)

0.002a,c

Endometrial thickness (mm)

9.6(8.63–10.6)

8(8–9.75)

9(8–10)

0.001a

Biochemical pregnancy rate per transfer (%)*

70.69%(41/58)

60.23%(53/88)

60.77%(79/130)

0.364

Clinical pregnancy rate per transfer (%)*

51.72%(30/58)

57.95%(51/88)

56.15%(73/130)

0.755

Implantation rate (%)*

51.72%(30/58)

57.95%(51/88)

56.15%(73/130)

0.755

Ongoing pregnancy rate per transfer (%)*

46.55%(27/58)

52.27%(46/88)

50%(65/130)

0.795

Miscarriage rate (%)*

7.32%(3/41)

9.43%(5/53)

12.66%(10/79)

0.637

Ectopic pregnancy rate (%)*

4.88%(2/41)

0.000

1.27%(1/79)

0.181

Live birth rate per transfer (%)*

43.1%(25/58)

45.45%(40/88)

39.23%(51/130)

0.648

Cumulative clinical pregnancy rate per woman (%)*

28.08%(41/146)

32.5%(52/160)

26.49%(80/302)

0.393

Cumulative live birth rate per woman (%)*

20.55%(30/146)

27.5%(44/160)

19.21%(58/302)

0.112

  1. aPPOS vs. GnRH agonist, p < 0.05
  2. bPPOS vs. GnRH antagonist, p < 0.05
  3. cGnRH agonist vs. GnRH antagonist, p < 0.05
  4. *p-value is considered to be significant when < 0.016 [Bonferroni correction (0.05/3)]